-
EP4216930
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4216930
| EP4216930 - CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.06.2023 Database last updated on 13.07.2024 | |
| Former | The international publication has been made Status updated on 02.04.2022 | Most recent event Tooltip | 06.07.2024 | Supplementary search report | published on 07.08.2024 [2024/32] | Applicant(s) | For all designated states Trisalus Life Sciences, Inc. 6272 West 91st Avenue Westminster, CO 90031 / US | [2023/31] | Inventor(s) | 01 /
KATZ, Steven, C. East Greenwich, RI 02818 / US | 02 /
COX, Bryan, F. Spring Grove, IL 60081 / US | 03 /
JAROCH, David, Benjamin Arvada, CO 80004 / US | [2023/31] | Representative(s) | Goddar, Heinz J. Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22 80336 München / DE | [2023/31] | Application number, filing date | 21873298.0 | 21.09.2021 | [2023/31] | WO2021US51384 | Priority number, date | US202063081613P | 22.09.2020 Original published format: US 202063081613 P | [2023/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022066673 | Date: | 31.03.2022 | Language: | EN | [2022/13] | Type: | A1 Application with search report | No.: | EP4216930 | Date: | 02.08.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.03.2022 takes the place of the publication of the European patent application. | [2023/31] | Search report(s) | International search report - published on: | US | 31.03.2022 | (Supplementary) European search report - dispatched on: | EP | 05.07.2024 | Classification | IPC: | A61K31/7125, A61P35/00, A61K9/00, A61K31/713, A61K39/00, A61K39/39, A61K45/06 | [2024/32] | CPC: |
A61K39/39 (EP,US);
A61K48/00 (KR);
C12N15/117 (US);
A61K31/711 (EP,KR);
A61K31/7125 (EP);
A61K39/395 (EP);
A61K39/39558 (US);
A61K45/06 (EP,KR);
A61P35/00 (EP,KR,US);
C07K16/2818 (EP);
A61K2039/54 (EP,US);
A61K2039/545 (US);
A61K2039/55561 (EP,US);
A61M2025/0002 (EP);
A61M2025/0042 (EP);
| C-Set: |
A61K31/7125, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP) |
| Former IPC [2023/31] | A61K9/00, A61K31/7115, A61K31/7125, A61K31/713, A61K39/00, A61K39/39 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/31] | Title | German: | KREBSTHERAPIE MIT TOLL-LIKE-REZEPTORAGONISTEN | [2023/31] | English: | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS | [2023/31] | French: | THÉRAPIE ANTICANCÉREUSE UTILISANT DES AGONISTES DU RÉCEPTEUR DE TYPE TOLL | [2023/31] | Entry into regional phase | 22.03.2023 | National basic fee paid | 22.03.2023 | Search fee paid | 22.03.2023 | Designation fee(s) paid | 22.03.2023 | Examination fee paid | Examination procedure | 22.03.2023 | Examination requested [2023/31] | Fees paid | Renewal fee | 27.09.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2016058993 (LOWSKY ROBERT [US], et al); | [XY]US2017326232 (GUIDUCCI CRISTIANA [US], et al); | [XY]US2018169229 (YU YING [US], et al); | [Y]US2019298983 (JAROCH DAVID BENJAMIN [US], et al); |